Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Operating Income (2016 - 2025)

Sangamo Therapeutics has reported Operating Income over the past 16 years, most recently at -$38.2 million for Q4 2025.

  • Quarterly results put Operating Income at -$38.2 million for Q4 2025, down 46.99% from a year ago — trailing twelve months through Dec 2025 was -$121.2 million (down 16.61% YoY), and the annual figure for FY2025 was -$121.2 million, down 16.61%.
  • Operating Income for Q4 2025 was -$38.2 million at Sangamo Therapeutics, down from -$35.6 million in the prior quarter.
  • Over the last five years, Operating Income for SGMO hit a ceiling of $18.0 million in Q1 2023 and a floor of -$123.6 million in Q2 2023.
  • Median Operating Income over the past 5 years was -$45.5 million (2022), compared with a mean of -$44.2 million.
  • Biggest five-year swings in Operating Income: tumbled 1208.73% in 2021 and later surged 139.84% in 2023.
  • Sangamo Therapeutics' Operating Income stood at -$39.9 million in 2021, then plummeted by 38.83% to -$55.4 million in 2022, then dropped by 12.04% to -$62.1 million in 2023, then skyrocketed by 58.12% to -$26.0 million in 2024, then crashed by 46.99% to -$38.2 million in 2025.
  • The last three reported values for Operating Income were -$38.2 million (Q4 2025), -$35.6 million (Q3 2025), and -$17.9 million (Q2 2025) per Business Quant data.